Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Updates on HER2-low breast cancer

BGICC 2023

19 - 20 Jan 2023

Published: 2 Feb 2023

Views: 23

Rating:

Save

Prof Sana Al Sukhun - University of Jordan, Amman, Jordan

Prof Sana Al Sukhun speaks to ecancer about the latest in HER2-low breast cancer. She discusses the latest in HER2-low BC treatment with trastuzumab and the explores the survival outcomes.

Prof Al Sukhun also speaks about antibody-drug conjugates (ADCs) technologies for management of metastatic breast cancer.

Related Videos

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Survival outcomes in randomised controlled trials with first-line CDK4/6i in...

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Survival outcomes in randomised controlled trials with first-line CDK4/6i in HR+/HER2-Ve breast cancer ( Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Nirogacestat success for desmoid tumours

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat success for desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer